Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections; Juvenile rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms CHASE
- 13 Dec 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2018 Planned End Date changed from 1 Nov 2014 to 30 Sep 2018.
- 04 Mar 2018 Planned primary completion date changed from 1 Nov 2014 to 30 Jun 2018.